Combined Radio- and Chemotherapy of Brain Tumours in Adult Patients

Clinical Oncology

Volumn 21, Issue 7, 2009, Pages 515-524

  Nieder, C ^a,b   Mehta, M P ^c   Jalali, R ^d  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c University of Wisconsin Health   (United States)

^d TATA MEMORIAL HOSPITAL   (India)

Author keywords

Brain tumours; chemotherapy; glioma; medulloblastoma; radiotherapy; treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; LOMUSTINE; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PLACEBO; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ADJUVANT THERAPY; ARTICLE; ASTROCYTOMA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN CANCER; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; GLIOBLASTOMA; GLIOMA; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KARNOFSKY PERFORMANCE STATUS; MEDLINE; MEDULLOBLASTOMA; METHODOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PATIENT CARE; POSTOPERATIVE PERIOD; PREDICTION; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN METHYLATION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; STEREOTACTIC RADIOSURGERY; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS;

EID: 68049083711     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2009.05.003     Document Type: Article

References (75)

1. Ohgaki H., and Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 109 (2005) 93-108
2. Jalali R., and Datta D. Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neuro Oncol 87 (2008) 111-114
3. Nieder C., Andratschke N., Wiedenmann N., Busch R., Grosu A.L., and Molls M. Radiotherapy for high-grade gliomas: does altered fractionation improve the outcome?. Strahlenther Onkol 180 (2004) 401-407
4. Lorenzoni J., Torrico A., Villanueva P., et al. Surgery for high-grade gliomas in a developing country: survival estimation using a simple stratification system. Surg Neurol 70 (2008) 591-597
5. McGirt M.J., Chaichana K.L., Gathinji M., et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 110 (2009) 156-162
6. Stummer W., Reulen H.J., Meinel T., et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. J Neurosurg 62 (2008) 564-576
7. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 49 (1978) 333-343
8. Walker M.D., Strike T.S., and Sheline G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 5 (1979) 1725-1731
9. Bleehen N.M., and Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 64 (1991) 769-774
10. Irwin C., Hunn M., Purdie G., and Hamilton D. Delay in radiotherapy shortens survival in patients with high grade glioma. J Neuro Oncol 85 (2007) 339-343
11. Blumenthal D.T., Won M., Mehta M.P., et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the Radiation Therapy Oncology Group database. J Clin Oncol 27 (2009) 733-739
12. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85 (1993) 704-710
13. Roa W., Brasher P.M.A., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 22 (2004) 1583-1588
14. Keime-Guibert F., Chinot O., Taillandier L., et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 356 (2007) 1527-1535
15. Fine H.A., Dear K.B., Loeffler J.S., et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (1993) 2585-2597
16. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 (2002) 1011-1018
17. Westphal M., Hilt D.C., Bortey E., et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5 (2003) 79-88
18. Tolcher A.W., Gerson S.L., Denis L., et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88 (2003) 1004-1011
19. Van Rijn J., Heimans J.J., van den Berg J., van der Valk P., and Slotman B.J. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 47 (2000) 779-784
20. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 60 (2004) 853-860
21. Buckner J.C., Ballman K.V., Michalak J.C., et al. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 trials. J Clin Oncol 24 (2006) 3871-3879
22. Fisher B., Won M., McDonald D., et al. Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53 (2002) 980-986
23. Langer C.J., Ruffer J., Rhodes H., et al. Phase II Radiation Therapy Oncology Group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51 (2001) 113-119
24. Stupp R., Dietrich P.Y., Ostermann Kraljevic S., et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20 (2002) 1375-1382
25. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
26. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26 (2008) 2192-2197
27. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol 23 (2005) 2372-2377
28. Lee S.M., Brada M., Stenning S., et al. A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12, ISRCTN83176944). Ann Oncol 19 Suppl 8 (2008) viii2 [abstract]
29. Kocher M., Frommolt P., Borberg S.K., et al. Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 184 (2008) 572-579
30. Lamers L.M., Stupp R., van den Bent M.J., et al. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE-3 intergroup study. Cancer 112 (2008) 1337-1344
31. Combs S.E., Wagner J., Bischof M., et al. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 71 (2008) 999-1005
32. Von Bossanyi P., Diete S., Dietzmann K., et al. Immunohistochemical expression of P-glycoprotein and glutathione S-transferases in cerebral gliomas and response to chemotherapy. Acta Neuropathol 94 (1997) 605-611
33. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
34. Jalali R., Basu A., Gupta T., et al. Encouraging experience of concomitant temozolomide with radiotherapy followed by adjuvant temozolomide in newly diagnosed glioblastoma multiforme: single institution experience. Br J Neurosurg 21 (2007) 583-587
35. Choi J.W., Lee M.M., Kim I.A., et al. The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high-grade gliomas: the preliminary results of single center prospective study. J Korean Neurosurg Soc 44 (2008) 222-227
36. Back M.F., Ang E.L.L., Ng W.H., et al. Improved median survival for glioblastoma multiforme following introduction of adjuvant temozolomide chemotherapy. Ann Acad Med Singap 36 (2007) 338-342
37. Yaman E., Buyukberber S., Uner A., et al. Temozolomide in newly diagnosed malignant gliomas: administered concomitantly with radiotherapy, and thereafter as consolidation treatment. Onkologie 31 (2008) 309-313
38. Grossman S.A., O'Neill A., Grunnet M., et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21 (2003) 1485-1491
39. Chakravarti A., Chakladar A., Delaney M.A., et al. The epidermal receptor growth factor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 62 (2002) 4307-4315
40. Eshleman J.S., Carlson B.L., Mladek A.C., et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 62 (2002) 7291-7297
41. Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3′-kinase signalling pathway in glioblastoma patients in vivo. Cancer Res 63 (2003) 2742-2746
42. Lammering G., Hewit T.H., Valerie K., et al. Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int J Radiat Biol 79 (2003) 561-568
43. Nieder C., Schlegel J., Andratschke N., Thamm R., Grosu A.L., and Molls M. The role of growth factors in central nervous system tumours. Anticancer Res 23 (2003) 1681-1686
44. Prados M.D., Scott C., Curran W.J., et al. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: a retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17 (1999) 3389-3395
45. Brandes A.A., Nicolardi L., Tosoni A., et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol 8 (2006) 253-260
46. Lebrun C., Fontaine D., Ramaioli A., et al. Long-term outcome of oligodendrogliomas. Neurology 62 (2004) 1783-1787
47. Van den Bent M., Chinot O.L., and Cairncross J.G. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro Oncol 5 (2003) 128-138
48. Vogelbaum M.A., Berkey B., Peereboom D., et al. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: RTOG BR0131. Neuro Oncol 11 (2009) 167-175
49. Intergroup Radiation Therapy Oncology Group trial 9402, Cairncross G., Berkey B., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group trial 9402. J Clin Oncol 24 (2006) 2707-2714
50. Cairncross G., Wang M., Chang S., et al. A randomized trial of chemotherapy plus radiotherapy (RT) vs RT alone for anaplastic oligodendroglioma (RTOG 9402): the perspective of longer follow-up. Int J Radiat Oncol Biol Phys 72 Supp l (2008) S7-S8 [abstract]
51. Van den Bent M.J., Carpentier A.F., Brandes A.A., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24 (2006) 2715-2722
52. Kocher M., Kunze S., Eich H.T., et al. Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 181 (2005) 157-163
53. Carrie C., Muracciole X., Gomez F., et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. Int J Radiat Oncol Biol Phys 63 (2005) 711-716
54. Taylor R.E., Bailey C.C., Robinson K.J., et al. Impact of radiotherapy parameters on outcome in the International Society of Pediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. Int J Radiat Oncol Biol Phys 58 (2004) 1184-1193
55. Packer R.J., Gaijjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 (2006) 4202-4208
56. Douglas J.G., Barker J.L., Ellenbogen R.G., et al. Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. Int J Radiat Oncol Biol Phys 58 (2004) 1161-1164
57. Ang C., Hauerstock D., Guiot M.C., et al. Characteristics and outcomes of medulloblastoma in adults. Pediatr Blood Cancer 51 (2008) 603-607
58. Herrlinger U., Steinbrecher A., Rieger J., et al. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol 252 (2005) 291-299
59. Abacioglu U., Uzel O., Sengoz M., Turkan S., and Ober A. Medulloblastoma in adults: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 54 (2002) 855-860
60. Lai R. Survival of patients with adult medulloblastoma. Cancer 112 (2008) 1568-1574
61. Brandes A.A., Franceschi E., Tosoni A., Blatt V., and Ermani M. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer 110 (2007) 2035-2041
62. Selek U., Zorlu F., Hurmuz P., et al. Craniospinal radiotherapy in adult medulloblastoma. Strahlenther Onkol 183 (2007) 236-240
63. Padovani L., Sunyach M.P., Perol D., et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys 68 (2007) 433-440
64. Abrey L.E., Ben-Porat L., Panageas K.S., et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24 (2006) 5711-5715
65. Haldorsen I.S., Krossnes B.K., Aarseth J.H., et al. Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003. Cancer 110 (2007) 1803-1814
66. Rujirojindakul P., Rohitoprakarn M., Kongkabpan D., Viboonjantra P., and Lekhakula A. Incidence and radiographic findings of primary central nervous system lymphoma in immunocompetent patients in southern Thailand. Tumori 94 (2008) 304-308
67. Kiewe P., Fischer L., Martus P., Thiel E., and Korfel A. Primary central nervous system lymphoma. Cancer 112 (2008) 1812-1820
68. Illerhaus G., Marks R., Müller F., et al. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20 (2009) 319-325
69. Omuro A.M., Taillandier L., Chinot O., Carnin C., Barrie M., and Hoang-Xuan K. Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neuro Oncol 85 (2007) 207-211
70. Ekenel M., Iwamoto F.M., Ben-Porat L.S., et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 113 (2008) 1025-1031
71. Gavrilovic I.C., Hormigo A., Yalahom J., Deangelis L.M., and Abrey L.E. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24 (2006) 4570-4574
72. Illerhaus G., Marks R., Ihorst G., et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24 (2006) 3865-3870
73. Shah G.D., Yahalom J., Correa D.D., et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25 (2007) 4730-4735 [erratum 2008;26:340]
74. Fisher B., Seiferheld W., Schultz C., et al. Secondary analysis of Radiation Therapy Oncology Group study 9310: an Intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neuro Oncol 74 (2005) 201-205
75. Kreisl T.N., Panageas K.S., Elkin E.B., Deangelis L.M., and Abrey L.E. Treatment pattern and prognosis in patients with human immunodeficiency virus and primary central nervous system lymphoma. Leuk Lymphoma 49 (2008) 1710-1716